CG Oncology (CGON) to Release Quarterly Earnings on Thursday

CG Oncology (NASDAQ:CGON - Get Free Report) is anticipated to release its Q1 2025 earnings data before the market opens on Thursday, May 8th. Analysts expect CG Oncology to post earnings of ($0.36) per share for the quarter.

CG Oncology (NASDAQ:CGON - Get Free Report) last issued its quarterly earnings data on Tuesday, March 25th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.11). The company had revenue of $0.46 million for the quarter, compared to the consensus estimate of $0.11 million. CG Oncology had a negative return on equity of 18.97% and a negative net margin of 10,642.98%. On average, analysts expect CG Oncology to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

CG Oncology Price Performance

Shares of NASDAQ:CGON traded down $1.12 during trading on Tuesday, hitting $27.06. The company had a trading volume of 260,351 shares, compared to its average volume of 969,007. The stock has a market cap of $2.06 billion, a price-to-earnings ratio of -19.06 and a beta of 1.08. The company has a fifty day simple moving average of $23.74 and a two-hundred day simple moving average of $28.85. CG Oncology has a one year low of $14.80 and a one year high of $40.47.

Analysts Set New Price Targets

A number of research firms have weighed in on CGON. TD Cowen started coverage on shares of CG Oncology in a research report on Tuesday, January 7th. They set a "buy" rating on the stock. Royal Bank of Canada increased their price objective on shares of CG Oncology from $66.00 to $68.00 and gave the stock an "outperform" rating in a research report on Tuesday, April 29th. Morgan Stanley reissued an "overweight" rating and issued a $55.00 price objective on shares of CG Oncology in a research note on Friday, March 7th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $75.00 target price on shares of CG Oncology in a research note on Monday, April 28th. Finally, Scotiabank began coverage on CG Oncology in a research note on Wednesday, April 16th. They set a "sector perform" rating and a $23.00 price target for the company. One investment analyst has rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, CG Oncology currently has a consensus rating of "Buy" and a consensus price target of $57.70.

Insider Transactions at CG Oncology

In other CG Oncology news, Director Leonard E. Post sold 1,000 shares of the firm's stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $30.76, for a total transaction of $30,760.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.